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Highlights 
 The SNP rs12807809 in NRGN is a promising risk variant identified for 
schizophrenia by genome-wide association studies.  
 We investigated the association of NRGN rs12807809 in 1005 Schizophrenia 
patients and 1069 controls in South Indian population. 
 The rs12807809 in NRGN showed a significant difference between cases and 
controls and is associated with Schizophrenia. 
 The minor non-risk allele ‘C’ contributes to the severity of psychosis in this 
study population. 
 
Abstract 
Schizophrenia (SCZ) as a severe and complex neuropsychiatric disorder and is characterized 
by positive symptoms, negative symptoms and cognitive dysfunctions. Genome-wide 
association studies (GWAS) have identified a strong association between the single nucleotide 
polymorphism (SNP) rs12807809 upstream of Neurogranin (NRGN) in a European 
population. This evidence prompted us to conduct an association study among 1,005 
schizophrenia cases and 1,069 controls in a South Indian Population using TaqMan Allelic 
discrimination method. We observed an association of rs12807809 with SCZ in this study 
population. Allele frequencies and genotype frequencies of rs12807809 showed significant 
differences between cases and control subjects [p=0.0019; OR = 0.69; 95% CI = (0.55 – 0.87)] 
and (p=0.0062). Further Genotype-Phenotype correlation revealed a moderate association of 
rs12807809 with flat affect (p=0.039) and Hallucinations (p=0.012). The ancestral non-risk C 
allele contributes to the severity of psychosis (p=0.039) in this population. 
 
Keywords: NRGN genotype, rs12807809, Cases Control study, GWAS Replication, 
Schizophrenia.  
 
Introduction 
Schizophrenia (SCZ) a severe and complex neuropsychiatric disorder, has a lifetime 
prevalence of ~1% which constituting ~ 1% of the global burden of disease (GBD) [1]. SCZ is 
characterized by positive symptoms (hallucinations, delusions), negative symptoms 
(avolition, social withdrawal, reduced affective expression) and cognitive dysfunctions 
(attention, memory, executive functions, etc.). Genetic epidemiology of SCZ has documented 
a heritability of ~ 80%, highlighting a major role for inherited genetic variants in the etiology 
of schizophrenia. Family, twin and adoption studies have consistently demonstrated genetic 
component to schizophrenia, together with developmental and environmental influences. 
The onset of large-scale genome-wide association and copy number variation (CNV) studies 
has led to rapid advances in our understanding of the genetic architecture of schizophrenia. 
A growing number of common SNPs and rare CNVs have now been replicated, including some 
that hint at possible novel aetiological mechanisms [2]. A combined GWAS analysis in 
European populations reported seven significant SNPs associated with SCZ [3], including 
rs12807809, located 3,457 bases upstream from the Neurogranin (NRGN) gene at 11q24.2. 
While the latest SCZ GWAS study by the Psychiatric Genomics Consortium (PGC) did not 
observe genome-wide significance for rs12807809, it did report strong support (p=4.114E-7) 
for this SNP [4]. Other studies in Han Chinese and Japanese populations have, however, failed 
to observe an association of this SNP with SCZ [5,6]. 
The Neurogranin (NRGN) gene on chromosome 11q24.2 spans 7.3 kb of genomic DNA and 
contains four exons. A genome-wide linkage study demonstrated that 11q23.3-24, wherein 
NRGN is located, was linked to SCZ (p=0.0003) [7]. NRGN regulates the release of CaM and 
the activities of downstream CaM-Ca2+-dependent enzymes that play an important role in 
the neuroplasticity mechanisms of learning and memory [8]. It has been shown to play a role 
in dendritic spine formation, synaptic plasticity, long-term potentiation and spatial learning, 
and is abundantly expressed in areas of the brain that are important for learning, memory 
and cognitive processing, particularly CA1 pyramidal neurons in the hippocampus [9]. Altering 
NRGN activity could mimic the effects of NMDA receptor hypofunction suggesting implication 
in the pathophysiology of SCZ [10]. Based on the above reports NRGN appears to be a key 
candidate gene for schizophrenia by its function and position. To the best of our knowledge 
this is the first report of this important polymorphism in an Indian population.  
 
Materials and Methods 
Subject selection: 
In this case-control study a total of 1005 SCZ patients were recruited from the Schizophrenia 
Research Foundation (SCARF), Chennai. Inclusion criteria were: (1) Consensus diagnosis of 
Schizophrenia/Schizoaffective disorder based on the Diagnostic and Statistical Manual of 
Mental Disorders, fourth edition (DSM-IV-TR) by experienced psychiatrists; (2) Tamil Indian 
ethnicity with biological parents and grandparents having the same ethnic background. 
Exclusion criteria for individuals were: (1) age less than 18 years; (2) inability to give informed 
consent; (3) psychosis judged to be secondary to substance use or a known neurological 
disorder such as epilepsy; and (4) severe mental retardation [11,12]. Healthy controls 
(N=1069) from similar ethnic groups were recruited for this study. Subjects having a first 
degree relative with severe mental illness and/or Mental retardation were excluded. Written 
informed consent was obtained from all the participants and the study was carried out with 
prior approval from the Institutional Ethics Committee of SCARF, Chennai. 
 
Clinical Diagnosis 
All patients were assessed using the Diagnostic Interview for Genetic Studies (DIGS)  [13]  and 
Family Interview for Genetic Studies (FIGS) [14]  instruments. DIGS is a structured interview 
for studies of psychiatric disorders and covers relevant history including age of onset of illness, 
duration of untreated psychoses, and symptom history, both medical and psychiatric. The 
psychosis section of DIGS covers positive and negative symptoms with the severity of the 
symptoms rated using the Schedule for Assessment of Positive (SAPS) and Negative (SANS)  
[15,16] . Symptoms are rated on a six point scale with scores ranging from “0” (none) to “5” 
(severe). Positive symptoms (SAPS) include Hallucinations, Delusions, Bizzare Behaviour and 
Thought disorder while Negative Symptoms (SANS) include Affective flattening, Alogia, 
Avolition/Apathy, Anhedonia/Asociality and Attention. The DIGS also includes longitudinal 
assessment of course and pattern of illness as well as severity in functional deterioration that 
is rated on a five-point scale from ‘episodic shift’ (1) to ‘relatively stable’ (5) with the higher 
score denoting worse outcome.  
The FIGS is a structured interview conducted with a family informant to identify and collect 
history of the illness about their ill relatives as well as constructing a pedigree chart with 
information regarding the presence of family history of mental illness (in up to three 
generations) and consanguinity in marriages (up to 3rd degree). All the data from the DIGS 
and FIGS were collated into a clinical summary which was reviewed by independently by two 
experienced psychiatrists who together subsequently arrived at a consensus diagnosis of the 
case according to DSM-IV-TR criteria.  
The controls were screened using the General Screening Questionnaire (GSQ) from the FIGS 
for screening out those with both a personal history of mental illness as well as a family history 
(first degree) of mental illness. 
 
SNP genotyping 
The peripheral venous blood samples were collected in EDTA tubes and genomic DNA was 
extracted from whole blood sample by the salting out method [17]. Genotyping of the 
rs12807809 polymorphism was conducted using high-throughput fluorescence-based 
TaqMan SNP Genotyping Assay (Assay ID: C_32029000_20, Applied Biosystems, Foster City, 
CA). The assay was performed in 384 well microtiter plates containing 10 ng DNA and TaqMan 
Mastermix (Applied Biosystems, USA) in a total 5 μl reaction. The reaction mixture was 
amplified with the following thermal cycling conditions: 2 min at 50°C, 10 min at 95°C followed 
by 40 cycles of 15 sec at 92°C and 60 sec at 60°C. Allelic discrimination with end point 
detection of fluorescence was performed using ABI 7900 real-time PCR system (Applied 
Biosystems, Foster City, CA). Genotypes were called using an automated allele scoring 
software SDS v 2.1 with confidence value of 95% and analysed with TaqMan SNP Genotyper 
Module v1.0. 
 
Statistical analysis 
Statistical analyses were performed with the R program (R Core Team, 2015). The data were 
analysed by χ2 test for goodness-of-fit using the GENETICS package (Gregory Warnes, 2013) 
to know whether the samples were in Hardy-Weinberg equilibrium. Pearson’s chi-square test 
and Fisher’s exact test were used for association analysis of genotypes using EPITOOLS 
package (Tomas J. Aragon, 2012). Chi-Square Test of Independence by contingency table 
calculated in SPSS 22 (IBM SPSS Statistics for Windows, Version 22.0. Armonk, NY: IBM Corp.) 
were used to test association between the NRGN genotype and clinical characteristics. All P-
values were two-tailed, and P-value less than 0.05 was considered as statistically significant. 
 
 
Results 
Genotyping analysis of the NRGN SNP rs12807809 was conducted in 1005 SCZ patients 
(Male=501; Female=504) and 1069 controls (Male=721; Female=348). Bio-Demographic 
details of patients and controls are listed in Table 1. The mean age did not differ significantly 
between cases and controls (p =0.3785); however, the male female ratio of the controls was 
higher than that of patients. The genotype frequencies of the rs12807809 in the patients and 
controls with the Odds ratio and p-value are shown in Table 2. The χ2 goodness-of-fit test 
demonstrated that the distributions of the NRGN SNP rs12807809 genotypes were consistent 
with Hardy-Weinberg equilibrium in controls (p = 0.61). In patients, there was an acceptable 
deviation in HWE (p = 0.008) providing additional support for an association of the marker 
locus with the disease. 
The marker rs12807809 in NRGN shows an association with SCZ in this study population. Allele 
(p=0.0019) and genotypic frequencies (p = 0.0062) of rs12807809 showed significant 
differences between the cases and control. However, the SNP had the opposite direction of 
effect (OR = 0.69, 95% CI = 0.55 – 0.87) compared to previously reported GWAS. 
 
Assessment of Clinical characteristics with genotype 
Analysis of genotype and clinical characteristics were done by test of independence by cross 
tabulation. When the subjects were sub grouped by gender, there was no significant sex-
specific associations for this marker. Further clinical details were analysed in 561 
schizophrenia patients. Age of onset was grouped as early (<=14), common (15-45), late onset 
(>45) and no significant association was observed between genotype and age of onset 
(p=0.136). Moreover, no association was observed with family history and consanguinity. A 
moderate association was observed with the rs12807809 for flat affect (p=0.039), 
hallucinations (p=0.012) and pattern of disease severity (p=0.039) although after applying the 
Bonferroni correction (α=0.003) clinical association was no longer significant. Interestingly, 
the non-risk C allele of rs12807809 polymorphism seems to contributes to the severity of 
psychosis in this study population (Table 3).  
 
 
Discussion 
Schizophrenia as a severe mental disorder with a lifetime risk of approximately 1% and is 
characterized by positive symptoms, negative symptoms and cognitive dysfunctions. 
Genome-wide association and follow-up studies have reported an association between SCZ 
and rs12807809 of the NRGN gene on chromosome 11q24.2. The chromosomal region 
11q23.3-24, including the NRGN gene, is linked to SCZ in British and Icelandic populations, 
confirmed by a genome-wide genetic linkage analysis [7]. The marker rs12807809 of NRGN 
gene attain genome wide significance (p = 2.4 × 10−9) when studied in 12,945 schizophrenia 
patients and 34,591 healthy control from eight European locations [3]. A recent Schizophrenia 
PGC study conducted a mega-analysis using 36,989 cases and 113,075 controls did not 
observe genome-wide significance but it did report strong support (p=4.114E-7) for this SNP  
[4]   In contrast to genome-wide significance in Caucasian populations, replication studies in 
Han Chinese (p = 0.36, odds ratio = 1.04, 95% CI = (0.96, 1.12) [5] and Japanese populations 
(p = 0.25, odds ratio = 1.06 (0.96–1.16) [6] showed no association. Furthermore, a meta-
analysis of rs12807809 in 4269 Han Chinese cases and 6962 controls also failed to show any 
association with the disease [18]. These contrasting results may be reflect ethnic differences. 
 
In the present replication study a total 2074 cases and control subjects were analysed to 
validate the association between the marker rs12807809 and SCZ in a South Indian 
population. There was significant variation between patients and controls for allele and 
genotype distributions. Clinical correlations showed a moderate association of this SNP with 
hallucinations and flat affect. In this study population the non-risk C allele showed a moderate 
association with pattern of severity of disease. The opposite direction of effect of this SNP 
(OR = 0.69) suggests the risk of C allele in Indian population. Also difference may be due 
potential ethnic and environmental heterogeneity between Europeans and Indians, which is 
also reflected by the differences in allele frequencies of this SNP between populations (T 
allele, 0.83 in Europeans vs. 0.93 in Indian samples). Ohi et al., 2017 reported that 86 of 122 
genetic variations detected by a previous GWAS (PGC-II), showed significant genetic 
heterogeneities between East Asian and European populations [19]. 
 
Varying results of T allele/C allele contribution to disease were evidenced by the association 
of the SNP rs12807809 with endophenotype and brain imaging studies. No significant 
difference between TT carriers and CT/CC carriers was observed in Irish samples on any 
neuropsychological measures assessed [20]. Similarly, Rose et al. investigated NRGN 
genotype effects on brain activity during a spatial working memory task in healthy controls. 
This study reported a failure to disengage ventromedial prefrontal areas in rs12807809 risk 
allele TT homozygotes but found no effect on grey or white matter volume [21]. The NRGN 
expression of high-risk TG of rs12807809–rs12278912 haplotype is lower than that of the 
protective TA haplotype in immortalized lymphoblasts in Japanese samples [22]. 
In another study, carriers of risk allele of rs12807809 (T) were observed to have a smaller grey 
matter volume in the left anterior cingulate cortex (Brodmann area 32) than carriers of the 
non-risk allele (C) in patients with SCZ  [23]. The MRI study carried out in patients/controls to 
understand the impact of this polymorphism in brain morphology reported that TT genotype 
was associated with widespread cortical thinning involving frontal, parietal and temporal 
cortices compared with controls having same genotype. No volumetric difference in 
subcortical structures (hippocampus, thalamus, amygdala, basal ganglia) was observed 
between risk TT genotype in schizophrenia patients and controls [24]. In contrast, NRGN 
rs12807809 non-risk allele (C) carriers were reported to have reduced cortical grey matter 
thickness compared to risk allele homozygotes (TT) in an area comprising the right 
pericalcarine gyrus, the right cuneus, and the right lingual gyrus, suggesting the C allele as a 
potential risk allele [25]. In the Han population of south China, the C allele of rs12807809 was 
associated with a higher PANSS aggression subscale score, activation subscale score and 
higher scores of global symptoms than carriers of the T allele [26]. Similarly, in this study the 
non risk C allele contributes to the severity of psychosis in SCZ cases. 
The discordant results associated with the SNP rs12807809 in replication studies cannot 
eliminate the importance of NRGN with reference to its strong role in neuronal development, 
synaptic signalling, plasticity, learning and memory which are probably underlying SCZ 
symptoms. To the best of our knowledge this is the first replication study of this important 
polymorphism in an Indian population. The results indicate that rs12807809 may play a 
significant role in conferring susceptibility to schizophrenia and the minor C allele is 
associated with severity of psychosis in patients with SCZ in Indian population. 
This study contributes toward the establishment of NRGN as a susceptibility gene for 
schizophrenia South Indian Population. Further studies, including those using high density 
mapping and deep sequencing, are required to identify other common susceptibility variants 
within the NRGN. Considering that multiple SNPs within the same gene may be associated 
with SCZ and several other factors might interact with and/or regulate the NRGN, functional 
study dissecting the molecular basis of the schizophrenia pathogenesis is strongly warranted. 
 
Conflict of Interest 
The authors declare that they have no conflict of interests. 
 
Acknowledgement: 
We thank all of the individuals who participated in this study. This study was supported by a 
grant from the Department of Biotechnology, New Delhi to AKM (Grant No. 
BT/PR4820/MED/12/622/2013). RS was supported by Basic Scientific Research Fellowship 
from the University Grants commission, New Delhi. RS thank Dr. Vishnuprabu Durairajpandian 
and Dr. Deva Magendhra Rao for their support and gratefully acknowledge the infrastructural 
facilities provided by UGC-SAP, DST-FIST and DHR-MRU. 
 
  
References 
R Core Team. 2015. R: A language and environment for statistical computing. R Foundation 
for Statistical Computing, Vienna, Austria. URL http://www.R-project.org/ 
Tomas J. Aragon Developer. 2012. epitools: Epidemiology Tools. R package version 0.5-7. 
http://CRAN.R-project.org/package=epitools 
Gregory Warnes, with contributions from Gregor Gorjanc, Friedrich Leisch and Michael Man. 
2013. genetics: Population Genetics. R package version 1.3.8.1. http://CRAN.R-
project.org/package=genetics 
 [1]  A. Lora, R. Kohn, I. Levav, R. McBain, J. Morris, S. Saxena, Service availability and 
utilization and treatment gap for schizophrenic disorders: a survey in 50 low- and middle-
income countries., Bulletin of the World Health Organization. 90 (2012) 47–54, 54A–54B. 
[2]  B.J. Mowry, J. Gratten, The emerging spectrum of allelic variation in schizophrenia: 
current evidence and strategies for the identification and functional characterization of 
common and rare variants., Molecular Psychiatry. 18 (2013) 38–52. 
[3]  H. Stefansson, R. Ophoff, S. Steinberg, O. Andreassen, S. Cichon, D. Rujescu, et al., 
Common variants conferring risk of schizophrenia, Nature. 460 (2009) 744–747. 
[4]  Unknown, Biological insights from 108 schizophrenia-associated genetic loci., Nature. 
511 (2014) 421–7. 
[5]  T. Li, Z. Li, P. Chen, Q. Zhao, T. Wang, K. Huang, et al., Common variants in major 
histocompatibility complex region and TCF4 gene are significantly associated with 
schizophrenia in Han Chinese., Biological Psychiatry. 68 (2010) 671–3. 
[6]  K. Ohi, R. Hashimoto, Y. Yasuda, M. Fukumoto, H. Yamamori, S. Umeda-Yano, et al., 
Functional genetic variation at the NRGN gene and schizophrenia: evidence from a gene-
based case-control study and gene expression analysis., American Journal of Medical 
Genetics. Part B, Neuropsychiatric Genetics : The Official Publication of the International 
Society of Psychiatric Genetics. 159B (2012) 405–13. 
[7]  H.M. Gurling, G. Kalsi, J. Brynjolfson, T. Sigmundsson, R. Sherrington, B.S. Mankoo, et 
al., Genomewide genetic linkage analysis confirms the presence of susceptibility loci for 
schizophrenia, on chromosomes 1q32.2, 5q33.2, and 8p21-22 and provides support for 
linkage to schizophrenia, on chromosomes 11q23.3-24 and 20q12.1-11.23., American Journal 
of Human Genetics. 68 (2001) 661–73. 
[8]  J.H. Pak, F.L. Huang, J. Li, D. Balschun, K.G. Reymann, C. Chiang, et al., Involvement of 
neurogranin in the modulation of calcium/calmodulin-dependent protein kinase II, synaptic 
plasticity, and spatial learning: a study with knockout mice., Proceedings of the National 
Academy of Sciences of the United States of America. 97 (2000) 11232–7. 
[9]  F.L. Huang, K.-P.P. Huang, C. Boucheron, Long-term enrichment enhances the 
cognitive behavior of the aging neurogranin null mice without affecting their hippocampal 
LTP., Learning & Memory (Cold Spring Harbor, N.Y.). 14 (2007) 512–9. 
[10]  G. Tsai, J.T. Coyle, Glutamatergic mechanisms in schizophrenia., Annual Review of 
Pharmacology and Toxicology. 42 (2002) 165–79. 
[11]  E.G. Holliday, D.R. Nyholt, S. Tirupati, S. John, P. Ramachandran, M. Ramamurti, et al., 
Strong evidence for a novel schizophrenia risk locus on chromosome 1p31.1 in homogeneous 
pedigrees from Tamil Nadu, India., The American Journal of Psychiatry. 166 (2009) 206–15. 
[12]  R. Thara, T. Srinivasan, S. John, D. Nancarrow, D. Chant, E. Holliday, et al., Design and 
clinical characteristics of a homogeneous schizophrenia pedigree sample from Tamil Nadu, 
India., The Australian and New Zealand Journal of Psychiatry. 43 (2009) 561–70. 
[13]  J.I. Nurnberger, M.C. Blehar, C.A. Kaufmann, C. York-Cooler, S.G. Simpson, J. Harkavy-
Friedman, et al., Diagnostic interview for genetic studies. Rationale, unique features, and 
training. NIMH Genetics Initiative., Archives of General Psychiatry. 51 (1994) 849–59; 
discussion 863–4. 
[14]  E.M. Maxwell, Manual for the FIGS, Bethesda (MD): Clinical Neurogenetics Branch, 
National Institute of Mental Health. (1992). 
[15]  N.C. Andreasen, Scale for the assessment of negative symptoms (SANS), Department 
of Psychiatry, College of Medicine, The University of Iowa, 1984. 
[16]  N.C. Andreasen, Scale for the assessment of positive symptoms (SAPS), University of 
Iowa Iowa City, 1984. 
[17]  S.A. Miller, D.D. Dykes, H.F. Polesky, A simple salting out procedure for extracting DNA 
from human nucleated cells., Nucleic Acids Research. 16 (1988) 1215. 
[18]  Z. Wen, J. Chen, R.A. Khan, M. Wang, Z. Song, Z. Li, et al., Polymorphisms in NRGN are 
associated with schizophrenia, major depressive disorder and bipolar disorder in the Han 
Chinese population., Journal of Affective Disorders. 194 (2016) 180–7. 
[19]  K. Ohi, T. Shimada, T. Yasuyama, T. Uehara, Y. Kawasaki, Variability of 128 
schizophrenia-associated gene variants across distinct ethnic populations., Transl Psychiatry. 
7 (2017) e988. 
[20]  G. Donohoe, J. Walters, D. Morris, A. Costa, E. Rose, A. Hargreaves, et al., A 
neuropsychological investigation of the genome wide associated schizophrenia risk variant 
NRGN rs12807809, Schizophrenia Research. 125 (2011) 304–306. 
[21]  E. Rose, D. Morris, C. Fahey, I. Robertson, C. Greene, J. O’Doherty, et al., The effect of 
the neurogranin schizophrenia risk variant rs12807809 on brain structure and function., Twin 
Research and Human Genetics : The Official Journal of the International Society for Twin 
Studies. 15 (2012) 296–303. 
[22]  K. Ohi, R. Hashimoto, Y. Yasuda, K. Nemoto, T. Ohnishi, M. Fukumoto, et al., Impact 
of the Genome Wide Supported NRGN Gene on Anterior Cingulate Morphology in 
Schizophrenia, PLoS ONE. 7 (2012). 
[23]  K. Ohi, R. Hashimoto, Y. Yasuda, M. Fukumoto, H. Yamamori, S. Umeda-Yano, et al., 
Influence of the NRGN gene on intellectual ability in schizophrenia, Journal of Human 
Genetics. 58 (2013) 700–705. 
[24]  J. Thong, A. Qiu, M. Sum, C. Kuswanto, T. Tuan, G. Donohoe, et al., Effects of the 
Neurogranin Variant rs12807809 on Thalamocortical Morphology in Schizophrenia, PLoS 
ONE. 8 (2013). 
[25]  E. Walton, D. Geisler, J. Hass, J. Liu, J. Turner, A. Yendiki, et al., The Impact of Genome-
Wide Supported Schizophrenia Risk Variants in the Neurogranin Gene on Brain Structure and 
Function, PLoS ONE. 8 (2013). 
[26]  L. Su, J. Long, R. Pan, X. Xie, X. Mao, Y. Zhou, et al., Influence of NRGN rs12807809 
polymorphism on symptom severity in individuals with schizophrenia in the Han population 
but not the Zhuang population of south China., Acta Neuropsychiatrica. 27 (2015) 221–7 
  
Table 1. Demographic variables of Patients and Control Subjects 
 Schizophrenia 
(n=1005) 
Mean ± SD 
Controls (n=1069) 
Mean ± SD 
SOCIO-DEMOGRAPHIC   
Sex– Male/Female (%) 49.85/50.14 67.44/32.55 
Age (Years) 41.11 ± 11.71 38.73 ± 12.17 
Education (in Years) 9.18 ± 4.60  
Marital Status(Married/Never 
Married/Married but Single)% 
46.1/37.7/16.2  
CLINICAL   
Age of onset (Years) 26.59 ± 9.10  
Duration of Illness (Years) 13.25 ± 8.72  
FAMILY HISTORY   
Consanguinity (Yes/No) (%) 25.2/74.6  
Family History (Yes/No) (%) 32.4/66.7  
 
Table 2.Allele and genotype frequencies of rs12807809 and its association with Schizophrenia 
 Genotype Distribution (%) Allelic Distribution (%) 
HWE p - Value 
 CC CT TT C  T 
SCZ Cases 
(n=1005) 
1.7 15.8 82.5 9.61  90.4 0.008 
Controls 
(n=1069) 
0.6  12.4 86.9 6.8  93.2 0.6164 
     
Genetic Model Odds Ratio (95% CI) Chi-square p value 
Genotypic 
Association 
CC vs CT vs TT   10.159 0.0062 
Allelic Model  C vs T 0.69 (0.55 – 0.87) 9.964 0.0019 
 
Table 3. Association of rs12807809 with Pattern of severity 
 
NRGN rs12807809 Vs Pattern of severity  
 
Pattern of severity N (%) 
Total 
p-value Episodic 
shift 
Mild 
Deterioration 
Moderate 
deterioration 
Severe 
Deterioration 
Relatively 
stable 
NRGN 
rs12807809 
CC 3 (5) 4 (3.5) 9 (5) 14 (9.1) 6 (13) 36 (6.5)  
CT 5 (8.3) 15 (13) 30 (16.8) 27 (17.5) 12 (26.1) 89 (16.1) 0.039 
TT 52 (86.7) 96 (83.5) 140 (78.2) 113 (73.4) 28 (60.9) 429 (77.4)  
Total 60 (100) 115 (100) 179 (100) 154 (100) 46 (100) 554 (100)  
